Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s R&D’.
Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (
Innovative clinical trial methodologies can also speed up drug development, yet the survey findings indicate that respondents are not experimenting with these as much as they could. For example, only
Peter Schueler, MD, Senior Vice President, Drug Development Solutions, Neurosciences at ICON commented: “Neurodegenerative clinical research is exceptionally complex and challenging. The main two roadblocks survey respondents identified for innovative tools were costs and difficulty validating the impact. At ICON, we believe that the industry can make more use of lessons learned from recent successes in Alzheimer’s and continue to turn the tide in related indications such as Parkinson’s.”
Encouragingly, the survey revealed sponsors are not deterred from investing in R&D, especially in a diversified way. A large majority of respondents (
Interestingly, the survey findings suggest that collaboration across industry is also an underappreciated acceleration opportunity. Only
Peter Schueler observed: “The recent successes in developing treatments for Alzheimer's disease can be attributed, in part, to improvements in trial design and execution. Replicating and improving upon this initial clinical success is essential to alleviate the growing burden of neurodegenerative diseases. Further engagement is needed across the clinical trial ecosystem – with established platforms, advocacy groups, biotech and pharma – to examine how best to work together in a way that balances the practicalities and risks associated with this complex therapeutic research field.”
For further information on this whitepaper, please visit http://www.iconplc.com/CNS-trials
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in
ICON/ICLR-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108086626/en/
Media:
Claire Quinn, Corporate Communications, ICON
+353 87 4066091
claire.quinn@iconplc.com
Lisa Henry, Weber Shandwick (PR adviser)
+44 7785 458203
lhenry@webershandwick.com
Source: ICON plc